A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
← catalyst calendarNCT07354724 · readout ≤ 743 d
Sponsored by Denali Therapeutics Inc. (industry) · DNLI — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
32estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-12 | actual | When the study began enrolling |
| Primary completion | Aug 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Late-onset Pompe Disease
Intervention
- Drug: DNL952
Primary outcomes
what the primary-completion date above is the date OFIncidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)
measured 48 weeks
Incidence and severity of infusion-related reacations (IRRs)
measured 48 weeks
Permalink · DNLI's whole pipeline · Catalyst calendar · Every registered study · What changed